Methods of treating an inflammatory disorder include administering an effective amount of a compound represented by Structural Formula (I): Ring A is optionally substituted, contains zero, one, two, or three double bonds, and is optionally fused to an aliphatic, aryl or heteroaryl ring; X is an optionally substituted 1 to 3 carbon aliphatic chain that is optionally fused to a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring, wherein one or two carbons in X are optionally replaced with --O--, --S--, or --NR.sup.e--; Y is carbon or nitrogen; R.sub.1 and R.sub.2 are independently --H, --OH, --CN, --NO.sub.2, --NR.sup.fR.sup.g, halogen, optionally substituted alkyl, or optionally substituted alkoxy; or R.sub.1 and R.sub.2 together link the carbons to which they are bonded with a bond, --O--, --S--, or --NR.sup.h--; R.sub.3 and R.sub.4 are independently --H, --OH, --CN, --NO.sub.2, --NR.sup.iR.sup.j, halogen, optionally substituted alkyl, or optionally substituted alkoxy, or R.sub.4 is .dbd.O; or R.sub.3 and R.sub.4, taken together with the atoms to which they are bonded, form a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring that is optionally fused to a monocyclic or bicyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring; R.sup.e-R.sup.j are independently --H or optionally substituted alkyl; and each of the OSM signaling inhibitor compounds has at least one hydrogen atom bonded to an oxygen, nitrogen, or sulfur atom. The OSM signaling inhibitor compounds also include pharmaceutically acceptable salt or solvates of the compounds represented by Structural Formula (I).